We continue to advance our oral rare disease pipeline, which also includes BCX9250 for FOP and additional discovery programs for other rare diseases.īeyond that, we’ve always believed our legacy antiviral programs play an important role in public health. We have built a company focused on discovering, developing and commercializing oral drugs for rare diseases. Add to that market potential for 9930 in an established market of more than $4 billion for treatment of complement-mediated diseases, and we see a significant opportunity for even greater value creation. And we announced yesterday that we have a new composition of matter patent that will extend our patent protection by 4 years to 2039. Based on the clinical response and the customer demand, we expect Berotralstat will generate peak sales of north of $500 million. Both physicians and HAE patients are consistently stating strong demand for our oral medicine in our market research. Patients are experiencing significant benefit in our clinical trials. Let’s start with HAE and the value we expect to create with Berotralstat. We will share exciting data for 9930 in PNH patients with you for the first time today. Right alongside these approvals, we have a pipeline in a molecule with our oral Factor D inhibitor, BCX9930 for complement-mediated diseases, including PNH. And in Europe, our MAA was validated in March, and we expect approval about that time next year. We have a December 3 PDUFA date from the FDA. We expect our first global approval in Japan in the second half of the year. The company is set to receive 3 approvals within the next 12 months for Berotralstat. We are in an extraordinary position at BioCryst. Thank you, John, and thank you all for joining us this morning.
Stonehouse, BioCryst Pharmaceuticals, Inc. I’d now like to turn the call over to Jon Stonehouse. You should not place undue reliance on these forward-looking statements.įor additional information, including a detailed discussion of our risk factors, please refer to the company’s documents filed with the Securities and Exchange Commission, which can be accessed on our website. These statements are subject to known and unknown risks and uncertainties, which may cause our actual results, performance or achievements to be materially different from any future results or performance expressed or implied in this presentation. Following our remarks, we will answer your questions.īefore we begin, please note that today’s conference call will contain forward-looking statements, including those statements regarding future results, unaudited and forward-looking financial information as well as the company’s future performance and/or achievements. Bill Sheridan Chief Business Officer, Megan Sniecinski and Chief Commercial Officer, Charlie Gayer. Participating with me today are: CEO, Jon Stonehouse CFO, Anthony Doyle Chief Medical Officer, Dr.
Today’s press release and slides are available on our website.
#AIRDEV CANVAS MOBILE APP WRAPPER UPDATE#
And welcome to BioCryst’s First Quarter 2020 Corporate Update and Financial Results Conference Call. I would now like to turn the conference over to your host, Mr. And welcome to the BioCryst First Quarter 2020 Earnings Call.Īs a reminder, this conference call is being recorded. – Senior VP & Chief Business OfficerīioCryst Pharmaceuticals, Inc. – CEO, President & DirectorīioCryst Pharmaceuticals, Inc. – SVP of IR & Corporate CommunicationsīioCryst Pharmaceuticals, Inc.
– Senior VP & Chief Commercial OfficerīioCryst Pharmaceuticals, Inc. – Senior VP & CFOīioCryst Pharmaceuticals, Inc. BIRMINGHAM (Thomson StreetEvents) - Edited Transcript of BioCryst Pharmaceuticals Inc earnings conference call or presentation Wednesday, at 12: 30: 00pm GMTīioCryst Pharmaceuticals, Inc.
0 kommentar(er)
